"Single-Domain Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
| Descriptor ID |
D061905
|
| MeSH Number(s) |
D12.644.541.500.650.500.900 D12.776.124.486.485.680.650.500.900 D12.776.124.790.651.680.650.500.900 D12.776.377.715.548.680.650.500.897
|
| Concept/Terms |
VHH Immunoglobulin Fragments- VHH Immunoglobulin Fragments
- Fragments, VHH Immunoglobulin
- Immunoglobulin Fragments, VHH
- Nanobodies
- VHH Fragments
- Fragments, VHH
VNAR Immunoglobulin Fragments- VNAR Immunoglobulin Fragments
- Fragments, VNAR Immunoglobulin
- Immunoglobulin Fragments, VNAR
- VNAR Fragments
- Fragments, VNAR
|
Below are MeSH descriptors whose meaning is more general than "Single-Domain Antibodies".
Below are MeSH descriptors whose meaning is more specific than "Single-Domain Antibodies".
This graph shows the total number of publications written about "Single-Domain Antibodies" by people in this website by year, and whether "Single-Domain Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Single-Domain Antibodies" by people in Profiles.
-
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024 05 14; 8(9):2059-2073.
-
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nat Commun. 2024 Jan 04; 15(1):285.
-
A New in Silico Antibody Similarity Measure Both Identifies Large Sets of Epitope Binders with Distinct CDRs and Accurately Predicts Off-Target Reactivity. Int J Mol Sci. 2022 Aug 28; 23(17).
-
Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy. PLoS One. 2022; 17(3):e0264822.
-
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. MAbs. 2022 Jan-Dec; 14(1):2002236.
-
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. 2021 07; 595(7866):278-282.
-
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 01; 9(1):21-32.
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
-
A Comparison Between Cell, Protein and Peptide-Based Approaches for Selection of Nanobodies Against CD44 from a Synthetic Library. Protein Pept Lett. 2018; 25(6):580-588.
-
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLoS One. 2016; 11(8):e0159477.